tetano
Editor, Senior Moderator
Allergy
. 2022 Mar 7.
doi: 10.1111/all.15271. Online ahead of print.
Humoral immune response of Sinopharm/BBIBP COVID-19 vaccination before and after the booster immunization
Zhangkai J Cheng[SUP] 1 [/SUP], Huimin Huang[SUP] 1 [/SUP], Peiyan Zheng[SUP] 1 [/SUP], Mingshan Xue[SUP] 1 [/SUP], Jing Ma[SUP] 1 [/SUP], Zhiqing Zhan[SUP] 1 [/SUP], Hui Gan[SUP] 1 [/SUP], Yifeng Zeng[SUP] 1 [/SUP], Runpei Lin[SUP] 1 [/SUP], Shiyun Li[SUP] 1 [/SUP], Ruifen Zhong[SUP] 2 [/SUP], Siping Li[SUP] 2 [/SUP], Hongman Wang[SUP] 3 [/SUP], Baoqing Sun[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The inactivated Sinopharm/BBIBP COVID-19 vaccine has been widely used in the world and has joined the COVAX vaccine supply program for developing countries. It is also well adapted for usage in low- and middle-income nations due to their low storage requirements.
Objective: This study aims to report on the kinetics, durability, and neutralizing ability of the induced immunity of the BBIBP vaccine, as well as the intensified antibody response elicited by the booster.
Methods: A total of 353 healthy adult participants, aged 20-74 years, were recruited in this multi-center study. A standard dose of the BBIBP vaccine was administered (Month 0), followed by a second standard dose (Month 1), and a booster dose (after Month 7). Vaccine-induced virus-specific antibody levels (SARS-CoV-2-IgA/IgM/IgG), conventional virus neutralization test (cVNT), pseudovirus neutralization test (pVNT), and surrogate virus neutralization test (sVNT) were monitored over multiple time points.
Results: Neutralizing titers induced by the two doses of inactivated vaccine for COVID-19 peaked at Month 2 and declined to 33.89% at Month 6. Following the booster dose, elevated levels of antibodies were induced for IgA, IgG, and neutralizing antibodies, with neutralizing titer reaching 13.2 times that of before the booster.
Conclusion: By monitoring the antibody titer levels post-vaccination, this study has shown that serum antibody levels will decrease over time, but a notable spike in antibody levels post-booster highlights the anamnestic immune response. This signifies that the protection capability has increased following the injection of booster immunization.
Keywords: Coronavirus disease 2019; SARS-CoV-2; antibody persistence; booster; vaccine.
. 2022 Mar 7.
doi: 10.1111/all.15271. Online ahead of print.
Humoral immune response of Sinopharm/BBIBP COVID-19 vaccination before and after the booster immunization
Zhangkai J Cheng[SUP] 1 [/SUP], Huimin Huang[SUP] 1 [/SUP], Peiyan Zheng[SUP] 1 [/SUP], Mingshan Xue[SUP] 1 [/SUP], Jing Ma[SUP] 1 [/SUP], Zhiqing Zhan[SUP] 1 [/SUP], Hui Gan[SUP] 1 [/SUP], Yifeng Zeng[SUP] 1 [/SUP], Runpei Lin[SUP] 1 [/SUP], Shiyun Li[SUP] 1 [/SUP], Ruifen Zhong[SUP] 2 [/SUP], Siping Li[SUP] 2 [/SUP], Hongman Wang[SUP] 3 [/SUP], Baoqing Sun[SUP] 1 [/SUP]
Affiliations
- PMID: 35255171
- DOI: 10.1111/all.15271
Abstract
Background: The inactivated Sinopharm/BBIBP COVID-19 vaccine has been widely used in the world and has joined the COVAX vaccine supply program for developing countries. It is also well adapted for usage in low- and middle-income nations due to their low storage requirements.
Objective: This study aims to report on the kinetics, durability, and neutralizing ability of the induced immunity of the BBIBP vaccine, as well as the intensified antibody response elicited by the booster.
Methods: A total of 353 healthy adult participants, aged 20-74 years, were recruited in this multi-center study. A standard dose of the BBIBP vaccine was administered (Month 0), followed by a second standard dose (Month 1), and a booster dose (after Month 7). Vaccine-induced virus-specific antibody levels (SARS-CoV-2-IgA/IgM/IgG), conventional virus neutralization test (cVNT), pseudovirus neutralization test (pVNT), and surrogate virus neutralization test (sVNT) were monitored over multiple time points.
Results: Neutralizing titers induced by the two doses of inactivated vaccine for COVID-19 peaked at Month 2 and declined to 33.89% at Month 6. Following the booster dose, elevated levels of antibodies were induced for IgA, IgG, and neutralizing antibodies, with neutralizing titer reaching 13.2 times that of before the booster.
Conclusion: By monitoring the antibody titer levels post-vaccination, this study has shown that serum antibody levels will decrease over time, but a notable spike in antibody levels post-booster highlights the anamnestic immune response. This signifies that the protection capability has increased following the injection of booster immunization.
Keywords: Coronavirus disease 2019; SARS-CoV-2; antibody persistence; booster; vaccine.